Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.

[1]  K. Flaherty,et al.  Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. , 2008, The Journal of investigative dermatology.

[2]  P. Valent,et al.  Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. , 2007, The Journal of investigative dermatology.

[3]  M. Röcken,et al.  Calcineurin inhibitors and rapamycin: cancer protection or promotion? , 2007, Experimental dermatology.

[4]  P. Valent,et al.  CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotranplantation Model , 2007, Pharmacology.

[5]  K. Flaherty.  Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma , 2006, Clinical Cancer Research.

[6]  R. Stahel,et al.  Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation , 2005, International journal of cancer.

[7]  J. Gills,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.

[8]  J. Doroshow,et al.  CCI‐779 in metastatic melanoma , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Wipf,et al.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. , 2004, Molecular cancer therapeutics.

[10]  G. Koehl,et al.  Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic Cancer , 2004, Clinical Cancer Research.

[11]  D. Neuberg,et al.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Markus Guba,et al.  Blockage of 2-Deoxy-d-Ribose-Induced Angiogenesis with Rapamycin Counteracts a Thymidine Phosphorylase-Based Escape Mechanism Available for Colon Cancer under 5-Fluorouracil Therapy , 2004, Clinical Cancer Research.

[13]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.